Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
Abstract Objective To evaluate the therapeutic impact of reduced glutathione combined with entecavir on liver function, fibrosis, and HBV-DNA clearance in chronic hepatitis B patients. Methods This was a randomized controlled trial. This study included 90 patients diagnosed with chronic hepatitis B,...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03600-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862238974312448 |
|---|---|
| author | Qiyao Wei Jing Zhao |
| author_facet | Qiyao Wei Jing Zhao |
| author_sort | Qiyao Wei |
| collection | DOAJ |
| description | Abstract Objective To evaluate the therapeutic impact of reduced glutathione combined with entecavir on liver function, fibrosis, and HBV-DNA clearance in chronic hepatitis B patients. Methods This was a randomized controlled trial. This study included 90 patients diagnosed with chronic hepatitis B, who were randomly divided into two groups (observation group and control group) using a random number table, with 45 patients in each group. The control group received standard entecavir treatment (0.5 mg/time, once a day, continuous treatment for 3 months), while the observation group received a combination therapy of reduced glutathione and the standard entecavir treatment. Liver function markers (ALT, TBIL, AST, ALB), fibrosis markers (HA, PC III, LN), and liver fibrosis grades were assessed pre-and post-treatment. HBV-DNA negative conversion rates were recorded at 4, 12, 24, and 48 weeks. The incidence of adverse reactions, including nausea, vomiting, headache, and mild gastric discomfort, was recorded and compared between the two groups during the treatment period. Results ALT decreased from 348.96 ± 31.47 U/L to 31.11 ± 9.78 U/L in the observation group and from 347.90 ± 31.40 U/L to 56.90 ± 16.32 U/L in the control group (P < 0.05). TBIL decreased from 61.78 ± 4.94 µmol/L to 18.82 ± 2.93 µmol/L in the observation group and from 61.32 ± 4.93 µmol/L to 26.70 ± 4.44 µmol/L in the control group (P < 0.05). ALB increased from 29.65 ± 0.94 g/L to 48.76 ± 4.85 g/L in the observation group and from 29.77 ± 0.90 g/L to 34.12 ± 0.84 g/L in the control group (P < 0.05). The observation group showed greater reductions in HA, PC III, and LN, and improved liver fibrosis grades (P < 0.05). HBV-DNA negative conversion rates in the observation group were 15.56%, 35.56%, 60.00%, and 68.89% at 4, 12, 24, and 48 weeks, respectively, compared to 2.22%, 6.67%, 17.78%, and 42.22% in the control group (P < 0.05). Adverse reaction rates were 8.89% in the observation group and 20.00% in the control group (P > 0.05). Conclusion Reduced glutathione combined with entecavir significantly improves liver function, reduces liver fibrosis, and enhances HBV-DNA clearance in chronic hepatitis B patients without increasing adverse reactions. |
| format | Article |
| id | doaj-art-cd5f34f0f08544088346568a8e6d79db |
| institution | Kabale University |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-cd5f34f0f08544088346568a8e6d79db2025-02-09T12:39:30ZengBMCBMC Gastroenterology1471-230X2025-02-0125111110.1186/s12876-025-03600-zTherapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patientsQiyao Wei0Jing Zhao1School of Basic Medical Sciences, North China University of Science and TechnologySchool of Basic Medical Sciences, North China University of Science and TechnologyAbstract Objective To evaluate the therapeutic impact of reduced glutathione combined with entecavir on liver function, fibrosis, and HBV-DNA clearance in chronic hepatitis B patients. Methods This was a randomized controlled trial. This study included 90 patients diagnosed with chronic hepatitis B, who were randomly divided into two groups (observation group and control group) using a random number table, with 45 patients in each group. The control group received standard entecavir treatment (0.5 mg/time, once a day, continuous treatment for 3 months), while the observation group received a combination therapy of reduced glutathione and the standard entecavir treatment. Liver function markers (ALT, TBIL, AST, ALB), fibrosis markers (HA, PC III, LN), and liver fibrosis grades were assessed pre-and post-treatment. HBV-DNA negative conversion rates were recorded at 4, 12, 24, and 48 weeks. The incidence of adverse reactions, including nausea, vomiting, headache, and mild gastric discomfort, was recorded and compared between the two groups during the treatment period. Results ALT decreased from 348.96 ± 31.47 U/L to 31.11 ± 9.78 U/L in the observation group and from 347.90 ± 31.40 U/L to 56.90 ± 16.32 U/L in the control group (P < 0.05). TBIL decreased from 61.78 ± 4.94 µmol/L to 18.82 ± 2.93 µmol/L in the observation group and from 61.32 ± 4.93 µmol/L to 26.70 ± 4.44 µmol/L in the control group (P < 0.05). ALB increased from 29.65 ± 0.94 g/L to 48.76 ± 4.85 g/L in the observation group and from 29.77 ± 0.90 g/L to 34.12 ± 0.84 g/L in the control group (P < 0.05). The observation group showed greater reductions in HA, PC III, and LN, and improved liver fibrosis grades (P < 0.05). HBV-DNA negative conversion rates in the observation group were 15.56%, 35.56%, 60.00%, and 68.89% at 4, 12, 24, and 48 weeks, respectively, compared to 2.22%, 6.67%, 17.78%, and 42.22% in the control group (P < 0.05). Adverse reaction rates were 8.89% in the observation group and 20.00% in the control group (P > 0.05). Conclusion Reduced glutathione combined with entecavir significantly improves liver function, reduces liver fibrosis, and enhances HBV-DNA clearance in chronic hepatitis B patients without increasing adverse reactions.https://doi.org/10.1186/s12876-025-03600-zReduced glutathioneChronic hepatitis BTherapeutic effectLiver functionLiver fibrosis |
| spellingShingle | Qiyao Wei Jing Zhao Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients BMC Gastroenterology Reduced glutathione Chronic hepatitis B Therapeutic effect Liver function Liver fibrosis |
| title | Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients |
| title_full | Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients |
| title_fullStr | Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients |
| title_full_unstemmed | Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients |
| title_short | Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients |
| title_sort | therapeutic effects of reduced glutathione on liver function fibrosis and hbv dna clearance in chronic hepatitis b patients |
| topic | Reduced glutathione Chronic hepatitis B Therapeutic effect Liver function Liver fibrosis |
| url | https://doi.org/10.1186/s12876-025-03600-z |
| work_keys_str_mv | AT qiyaowei therapeuticeffectsofreducedglutathioneonliverfunctionfibrosisandhbvdnaclearanceinchronichepatitisbpatients AT jingzhao therapeuticeffectsofreducedglutathioneonliverfunctionfibrosisandhbvdnaclearanceinchronichepatitisbpatients |